CDER Review “Consistency” Is One Theme Of FDA Reorganization
Executive Summary
FDA's decision to transfer most product reviews from the biologics center to CDER underscores the transformation in the images of the two centers during the user fee era
You may also be interested in...
Biologics Approval Record Is “Excellent” Under PDUFA, FDA Says
The Center for Biologics Evaluation & Research's new product review performance has been "excellent" under the user fee program, FDA said
FDA Developing Reviewer Communications Policy; Draft Expected This Year
FDA is drafting an internal policy on communication with sponsors that will address some of the issues raised during the House Energy & Commerce Committee hearing into the handling of ImClone's BLA for Erbitux
FDA Developing Reviewer Communications Policy; Draft Expected This Year
FDA is drafting an internal policy on communication with sponsors that will address some of the issues raised during the House Energy & Commerce Committee hearing into the handling of ImClone's BLA for Erbitux